Home \ Expert Opinion \ Why Mexidol®?

Why Mexidol®?

Syndrome of attention deficit with hyperactivity as an interdisciplinary problem. Mexidol® children with ADHD

Age continuum of ischemic-hypoxic lesions of the brain. The use of Mexidol for ADHD in children and adults

Rehabilitation after Covid-19

Mexidol®. Rehabilitation after coronavirus

The effectiveness of Mexidol in a comorbid patient: with arterial hypertension, coronary heart disease, brain ischemia

Mexidol's effectiveness in a polymorbid patient

Features of conducting elderly patients in clinical practice

Mexidol®-Anti-Age (anti-aging) drug

Dorsopathy in general clinical practice

Mexidol® with degenerative diseases in the spine, neck pain, dizziness, brain ischemia

Time codes:

01:02
History of the drug Mexidol®
01:40
The mechanism of action of the drug Mexidol®
03:03
Mexidol® - pharmacological effects
03:54
Clinical effects and safety of Mexidol®
04:30
Security Profile
05:09
The optimal dose and duration of intravenous infusion and intramuscular injection
05:50
Mexol 125 mg, Mexidol® Fort 250 mg transition
06:20
Evidence base of the effectiveness of Mexidol
06:45
The results of the study of Epic
08:16
Clinical recommendations
09:40
Differences in Mexidol® and analogues.

Schukin Ivan Aleksandrovich - Ph.D., Associate Professor of the Department of Neurology, Neurosurgery and Medical Genetics LF RNIMU named after N.I. Pirogov

Announcement:

Schukin Ivan Alexandrovich - candidate of medical sciences, associate professor of the Department of Neurology of the Russian State Medical University, answers the main questions about the drug Mexol®. Why is Mexidol® so widely prescribed and popular among doctors and patients? What pharmacological and clinical effects does it have? What is the evidence base and methods of using the drug Mexidol®? Let's figure it out!

Find out more in the video " Mexidol® - the standard of antioxidant neurocytoprotection ."

All video next video

Syndrome of attention deficit with hyperactivity as an interdisciplinary problem. Mexidol® children with ADHD

Age continuum of ischemic-hypoxic lesions of the brain. The use of Mexidol for ADHD in children and adults

Rehabilitation after Covid-19

Mexidol®. Rehabilitation after coronavirus

The effectiveness of Mexidol in a comorbid patient: with arterial hypertension, coronary heart disease, brain ischemia

Mexidol's effectiveness in a polymorbid patient

Features of conducting elderly patients in clinical practice

Mexidol®-Anti-Age (anti-aging) drug

Dorsopathy in general clinical practice

Mexidol® with degenerative diseases in the spine, neck pain, dizziness, brain ischemia

Time codes:

01:02
History of the drug Mexidol®
01:40
The mechanism of action of the drug Mexidol®
03:03
Mexidol® - pharmacological effects
03:54
Clinical effects and safety of Mexidol®
04:30
Security Profile
05:09
The optimal dose and duration of intravenous infusion and intramuscular injection
05:50
Mexol 125 mg, Mexidol® Fort 250 mg transition
06:20
Evidence base of the effectiveness of Mexidol
06:45
The results of the study of Epic
08:16
Clinical recommendations
09:40
Differences in Mexidol® and analogues.

Block of articles on this topic

Mexidol: a spectrum of pharmacological effects

Author:
T.A. Voronin

Nii pharmacology named after V.V. Zakusov RAMS, Moscow

Original and reproduced drugs: what do the clinician need to know?

Author:
A.V. Schulkin, A.A. Filimonova
FSBEI in the Ryazan State Medical University of the Ministry of Health of Russia, Ryazan, Russia

Personal: To the question of evidence -based neuroprotective therapy: Focus on ethylmethylhydroxypyridine succinate

Authors:
A.I. Kochetkov, N.A. Shatalova, M.V. Klepikova, T.V. Filippova, O.D. Ostroumova

FSBEA DPO “Russian Medical Academy of Continuing Professional Education” of the Ministry of Health of Russia, Moscow

The results of a randomized double blind multicenter placebo-controlled in parallel groups of the study and safety of Mexidol with prolonged consistent therapy in patients in the acute and early recovery periods

Personal: the results of an international multicenter randomized double-blind-controlled study of evaluating the effectiveness of the effectiveness and safety of sequential therapy of patients with chronic brain ischemia with Mexidol and Mexidol Forte 250 (study of Memo)

Authors:
A.I. Fedin ¹ , V.V. Zakharov ² , M.M. Tanashian ³ , E.I. Chukanova ¹ , E.N. Majidova ⁴ , L.A. Shchepankevich ^5.6 , O.D. Ostroumova ⁷

THE INFORMATION IS INTENDED FOR HEALTHCARE AND PHARMACEUTICAL PROFESSIONALS. THIS INFORMATION IS NOT INTENDED AS A SUBSTITUTE FOR MEDICAL ADVICE.

Source of photos and images Shutterstock.com